Atlas Trials

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Clinical trial NCT05181618 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05181618
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Severe Hemophilia AModerate Hemophilia A
Start date
2022-06-20
Primary completion
2027-11-30
Enrollment
136

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.